We are live on ! Find out more
PACB icon

Pacific Biosciences

80 hedge funds and large institutions have $197M invested in Pacific Biosciences in 2013 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 36 increasing their positions, 27 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 27

7% more capital invested

Capital invested by funds: $184M → $197M (+$13.1M)

5% less call options, than puts

Call options by funds: $223K | Put options by funds: $234K

8% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 12

1% less funds holding

Funds holding: 8180 (-1)

Holders
80
Holders Change
-1
Holders Change %
-1.23%
% of All Funds
2.32%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
11
Increased
36
Reduced
27
Closed
12
Calls
$223K
Puts
$234K
Net Calls
-$11K
Net Calls Change
-$313K
Name Holding Trade Value Shares
Change
Change in
Stake
PPA
26
Parametric Portfolio Associates
Washington
$1.09M +$493K +107,309 +106%
WM
27
WS Management
Florida
$1.06M +$929K +202,400 New
EIM
28
Essex Investment Management
Massachusetts
$1.03M +$906K +197,310 New
RFC
29
Russell Frank Company
Washington
$922K -$967K -210,669 -62%
BIM
30
BlackRock Investment Management
Delaware
$851K -$11K -2,403 -1%
SIM
31
Spark Investment Management
New York
$818K -$82.6K -18,000 -10%
NFA
32
Nationwide Fund Advisors
Ohio
$777K +$23.6K +5,138 +4%
Arrowstreet Capital
33
Arrowstreet Capital
Massachusetts
$752K +$661K +143,863 New
Verition Fund Management
34
Verition Fund Management
Connecticut
$721K +$484K +105,394 +324%
Jacobs Levy Equity Management
35
Jacobs Levy Equity Management
New Jersey
$657K -$47.8K -10,400 -8%
WMSA
36
Weiss Multi-Strategy Advisers
New York
$628K -$138K -30,000 -20%
SG Americas Securities
37
SG Americas Securities
New York
$577K -$231K -50,290 -31%
Nomura Holdings
38
Nomura Holdings
Japan
$548K -$4.01K -874 -0.8%
AQR Capital Management
39
AQR Capital Management
Connecticut
$479K +$361K +78,594 +609%
EMG
40
Ellington Management Group
Connecticut
$464K +$407K +88,700 New
California State Teachers Retirement System (CalSTRS)
41
California State Teachers Retirement System (CalSTRS)
California
$453K +$2.3K +500 +0.6%
Charles Schwab
42
Charles Schwab
California
$448K
Deutsche Bank
43
Deutsche Bank
Germany
$424K -$367K -79,883 -50%
AllianceBernstein
44
AllianceBernstein
Tennessee
$411K -$44.1K -9,600 -11%
TA
45
Teachers Advisors
New York
$392K +$112K +24,470 +48%
CS
46
Credit Suisse
Switzerland
$387K -$359K -78,102 -51%
RhumbLine Advisers
47
RhumbLine Advisers
Massachusetts
$361K -$11K -2,400 -3%
BA
48
Boston Advisors
Massachusetts
$278K +$128K +27,859 +110%
Susquehanna International Group
49
Susquehanna International Group
Pennsylvania
$269K -$118K -25,677 -33%
MLICM
50
Metropolitan Life Insurance Company (MetLife)
New York
$223K

PACB Hedge Fund Activity: Q4 2013 in Review

80 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q4 2013, worth a combined $197M — up 7.2% from $184M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of PACB and 11 opened new positions — a net loss of 1 holder — while 27 trimmed existing stakes and 36 added.

The largest buyer was BlackRock Institutional Trust, adding an estimated $8.36M. The largest seller was Redmile Group, exiting entirely with an estimated $8.71M sold.

  • 80 institutional investors held Pacific Biosciences (PACB) as of Q4 2013, down from 81 in Q3 2013.
  • Funds reported $197M of Pacific Biosciences stock for Q4 2013, up 7.2% quarter-over-quarter.
  • 11 funds opened new Pacific Biosciences positions in Q4 2013 and 12 closed out, a net change of -1 holder.
  • The largest Pacific Biosciences buyer in Q4 2013 was BlackRock Institutional Trust, an estimated $8.36M added.
  • The largest Pacific Biosciences seller in Q4 2013 was Redmile Group, an estimated $8.71M sold.

Based on aggregated 13F filings for Q4 2013.